About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Ohio | 10,042 Studies Near You | Clareo Health

Clinical Trials LocationsOhio

Clinical Trials in Ohio

Discover 10,042 clinical trials near Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2701-2720 of 10,042 trials

Active Not RecruitingPhase 332 miles

The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

NCT06046820

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy

Inozyme Pharma27 participantsStarted Nov 2023

Aurora, Colorado, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +12 more locations

RECRUITINGNA32 miles

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06455475

This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers

Diabetic Foot Ulcer

Capsicure, LLC150 participantsStarted Oct 2024

Athens, Alabama, United States • Encino, California, United States • Hollywood, Florida, United States +8 more locations

Find Trials by Condition in Ohio

Breast Cancerin Ohio Lung Cancerin Ohio Prostate Cancerin Ohio Colorectal Cancerin Ohio Melanomain Ohio Leukemiain Ohio Lymphomain Ohio Pancreatic Cancerin Ohio Ovarian Cancerin Ohio Brain Cancerin Ohio Diabetesin Ohio

Data from ClinicalTrials.govTerms

RECRUITINGNA32 miles

Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery

NCT06949943

This clinical trial tests how well guided meditation, compared to silence, works to reduce pre-operative anxiety in patients undergoing cancer-directed surgery. Pre-operative anxiety affects patient experience and has been found to be a predictor of severe post-operative pain and chronic pain after surgery, influencing the success and quality of a patient's recovery. While medication is often prescribed to improve anxiety symptoms, research has showed that mindfulness techniques can be used to decrease anxiety, improve comfort, and can impact both psychological and physiologic symptoms. Completing pre-operative guided meditation may work well to reduce pre-operative anxiety in patients undergoing cancer directive surgery.

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Ohio State University Comprehensive Cancer Center200 participantsStarted Mar 2025

Columbus, Ohio, United States

TERMINATEDPhase 178 miles

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05757492

This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous \[NSCLC-NS\] and Hepatocellular carcinoma \[HCC\])

Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma

Coherus Oncology, Inc.22 participantsStarted Apr 2023

Orlando, Florida, United States • Detroit, Michigan, United States • Reno, Nevada, United States +1 more locations

RECRUITINGNA81 miles

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

NCT02235857

Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipidemic condition but the nephrotic condition (e.g, proteinuria and hypoproteinemia). Although the definitive mechanism by which the system may relieve nephrotic syndrome is unknown, it has been recognized as one of alternative therapies for refractory nephrotic syndrome including focal segmental glomerulosclerosis (FSGS) in Japan and referred in the Guidelines for the Treatment of Nephrotic Syndrome endorsed by The Japanese Society of Nephrology. This study is conducted as a post approval study imposed by Humanitarian Device Exemption (HDE) order to confirm the safety and efficacy of the Liposorber® LA-15 System in the treatment of drug-resistant pediatric primary FSGS.

Focal Segmental Glomerulosclerosis

Kaneka Medical America LLC35 participantsStarted May 2015

Loma Linda, California, United States • Los Angeles, California, United States • Wilmington, Delaware, United States +9 more locations

Active Not RecruitingPhase 195 miles

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685

This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic Syndromes+3 more

Orca Biosystems, Inc.255 participantsStarted Nov 2019

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +18 more locations

COMPLETEDPhase 397 miles

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

NCT05259917

This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients

Hereditary Angioedema

KalVista Pharmaceuticals, Ltd.136 participantsStarted Feb 2022

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +63 more locations

TERMINATEDPhase 3143 miles

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.

Lupus Erythematosus, Systemic

Janssen Research & Development, LLC516 participantsStarted Apr 2018

Anniston, Alabama, United States • Birmingham, Alabama, United States • Vestavia Hills, Alabama, United States +201 more locations

RECRUITINGNA146 miles

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

NCT04503395

The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

Aortic Aneurysm, Abdominal

FCRE (Foundation for Cardiovascular Research and Education)204 participantsStarted May 2021

La Jolla, California, United States • Stanford, California, United States • Gainesville, Florida, United States +29 more locations

COMPLETEDPhase 3196 miles

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT02076009

The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.

Multiple Myeloma

Janssen Research & Development, LLC569 participantsStarted Jul 2014

Little Rock, Arkansas, United States • Gainesville, Florida, United States • West Palm Beach, Florida, United States +142 more locations

COMPLETEDPhase 3196 miles

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

NCT03551626

The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.

Malignant Melanoma

Novartis Pharmaceuticals552 participantsStarted Aug 2018

Rosario, Sante Fe, Argentina • Buenos Aires, Argentina • Córdoba, Argentina +97 more locations

COMPLETEDPhase 2228 miles

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164

The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).

Sjögren's Syndrome

Amgen183 participantsStarted Dec 2019

Fullerton, California, United States • Upland, California, United States • Lawrenceville, Georgia, United States +59 more locations

Active Not RecruitingPhase 2322 miles

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

NCT03556332

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

Multiple Myeloma

Memorial Sloan Kettering Cancer Center41 participantsStarted Jul 2018

Birmingham, Alabama, United States • Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States +9 more locations

COMPLETEDPhase 4402 miles

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (\>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary objective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.

Rheumatoid ArthritisPsoriatic ArthritisSpondylarthritis

Jeffrey Curtis841 participantsStarted Nov 2021

Birmingham, Alabama, United States • Hoover, Alabama, United States • Hoover, Alabama, United States +5 more locations

Active Not RecruitingPhase 1/2402 miles

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

NCT03689699

MAGIC-8 is a two-arm, multicenter, phase 1b/2 study to assess the efficacy of immunotherapy with either Nivolumab (anti-PD-1) or Nivolumab plus BMS-986253 combined with ADT using Degarelix (LHRH antagonist) for men with hormone-sensitive prostate cancer and a rising prostate-specific antigen (PSA). The purpose of this study is to see whether immunotherapy with either Nivolumab alone or Nivolumab plus BMS-986253 combined with Degarelix, which suppresses testosterone, is safe and can decrease the chance that the cancer will come back. The primary objectives are to 1) determine the rate of PSA recurrence defined as a PSA \>0.2ng/ml for radical prostatectomy patients or PSA \>2.0ng/ml for patients who received primary radiation therapy at a time point of 10 months after start of therapy; and 2) determine the safety and tolerability of either nivolumab or nivolumab plus BMS-986253 in combination with degarelix in men with hormone-sensitive prostate cancer. The secondary objectives include determining relapse-free survival (RFS) and % change in PSA to immunotherapy alone.

Prostate CancerAdenocarcinoma of the Prostate

Mark Stein59 participantsStarted Oct 2018

Atlanta, Georgia, United States • New York, New York, United States • New York, New York, United States +1 more locations

Active Not RecruitingPhase 2414 miles

APX005M and Doxorubicin in Advanced Sarcoma

NCT03719430

This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy.

Soft Tissue Sarcoma

Alexander Z. Wei, MD27 participantsStarted Mar 2019

Duarte, California, United States • St Louis, Missouri, United States • New York, New York, United States

RECRUITINGNA583 miles

Promoting Early Intervention Timing and Attention to Language

NCT05853861

The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months. Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (incorporates JASPER intervention and Babble Bootcamp) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.

University of California, Los Angeles140 participantsStarted Nov 2024

Los Angeles, California, United States • Worcester, Massachusetts, United States

RECRUITINGPhase 1/2621 miles

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

NCT06942572

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.

Stargardt DiseaseStargardt Macular DegenerationStargardt Macular Dystrophy

Splice Bio57 participantsStarted Feb 2025

Aurora, Colorado, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDNA622 miles

A Digital Intervention to Improve Physical Activity and Sleep Behaviors in Youth With Psychiatric Diagnoses

NCT05505578

The goal of "GamerFit" is to test the delivery of a theory-based mHealth app that utilizes social support, exergaming, and telehealth coaching to improve PA levels, sleep, and psychiatric symptoms among youth participants (ages 13-17 y) with PD. In order to aid future intervention optimization, up to 65 participants with at least one PD will be randomized, with 30-35 using the GamerFit app with weekly telehealth coaching sessions and 30-35 using a commercial healthy habits app as a comparator group

Psychiatric Diagnosis

Pennington Biomedical Research Center62 participantsStarted Jan 2023

Baton Rouge, Louisiana, United States • North Andover, Massachusetts, United States

RECRUITINGNA1170 miles

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

NCT06098482

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.

Cochlear46 participantsStarted Feb 2024

Lone Tree, Colorado, United States • Melbourne, Victoria, Australia • Antwerp, Antwerp, Belgium +1 more locations

PreviousPage 136 of 503Next

Heart Diseasein Ohio